{"entity":{"id":"nct06810544","kind":"trial","name":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","aka":[],"tldr":"A phase 1/2 trial of TNG456, Abemaciclib in non-small-cell lung cancer and small-cell lung cancer, run by Tango Therapeutics, Inc., now recruiting.","summary":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss is a phase 1/2 interventional study registered as NCT06810544 by Tango Therapeutics, Inc., with 191 participants planned, started 2025-03-24 and due to reach its primary completion in 2027-03-31. Interventions recorded: TNG456, abemaciclib. Conditions listed: Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06810544","url":"https://clinicaltrials.gov/study/NCT06810544"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","glioblastoma"],"sections":[],"technologies":["cdk46-inhibitor"],"targets":[],"drugs":["tng456","abemaciclib"],"companies":["tango-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06810544","phase":"1/2","setting":"A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","sponsor":"Tango Therapeutics, Inc.","participation":[{"nct":"NCT06810544","source":"https://clinicaltrials.gov/study/NCT06810544","fetchedAt":"2026-10-07T16:55:06.589Z","studySha256":"d51c963e72c4f7554a87a72ad25a46a7dadf253ed701a2c58414de76d795c834","overallStatus":"RECRUITING","lastUpdatePosted":"2026-04-13","leadSponsor":"Tango Therapeutics, Inc.","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":191,"enrolmentType":"ESTIMATED","siteCount":15,"recruitingSiteCount":15,"countries":["United States"]}],"started":"2025-03-24","startedType":"actual","enrolled":191,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06810544/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"cdk46-inhibitor","kind":"technology","name":"CDK4/6 inhibitors","route":"/technologies/cdk46-inhibitor/"}],"drug":[{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/"},{"id":"tng456","kind":"drug","name":"TNG456","route":"/drugs/tng456/"}],"company":[{"id":"tango-therapeutics","kind":"company","name":"Tango Therapeutics","route":"/companies/tango-therapeutics/"}]}}